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Background: Multilineage differentiation, immunomodulation and secretion of trophic factors render mesenchymal
stromal cells (MSC) highly attractive for clinical application. Human platelet derivatives such as pooled human platelet
lysate (pHPL) and thrombin-activated platelet releasate in plasma (tPRP) have been introduced as alternatives to fetal
bovine serum (FBS) to achieve GMP-compliance. However, whereas both pHPL and tPRP support similar proliferation
kinetics of lipoaspirate-derived MSC (LA-MSC), only pHPL significantly accelerates bone marrow-derived MSC (BM-MSC)
expansion. To identify functionally bioactive factors affecting ex vivo MSC expansion, a differential proteomic approach
was performed and identified candidate proteins were evaluated within a bioassay.
Results: Two dimensional difference gel electrophoresis (2D-DIGE), MALDI-TOF analyses and complementary Western
blotting revealed 20 differential protein species. 14 candidate proteins occured at higher concentrations in pHPL
compared to tPRP and 6 at higher concentrations in tPRP. The candidate proteins fibrinogen and apolipoprotein A1
differentially affected LA- and BM-MSC proliferation.
In a second set of experiments, reference cytokines known to foster proliferation in FBS were tested for their effects in
the human supplements. Interestingly although these cytokines promoted proliferation in FBS, they failed to do so
when added to the humanized system.
Conclusions: The differential proteomic approach identified novel platelet derived factors differentially acting on
human MSC proliferation. Complementary testing of reference cytokines revealed a lack of stimulation in the human
supplements compared to FBS. The data describe a new coherent approach to combine proteomic technologies with
functional testing to develop novel, humanized, GMP-compliant conditions for MSC expansion.
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Mesenchymal stromal cells (MSC) offer great potential
for therapeutic application since they combine a number
of biological properties such as multilineage differenti-
ation, stromal support, immunomodulation, and secre-
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reproduction in any medium, provided the orwithin tissues, in general ex vivo expansion is required to
achieve a clinically-relevant cell dose. This has to comply
with good manufacturing practice (GMP) guidelines. Fetal
bovine serum (FBS) used in many protocols, however, is
critically rated by the regulatory authorities due to the
possible transmission of extraneous agents as well as
the risk of triggering host immune responses compris-
ing the therapeutic success [4-7]. A chemically-defined
medium sufficiently mimicking serum compounds to pro-
vide growth and attachment factors, buffering and detoxi-
fying agents, is still under development [5,8,9]. Currently
human supplements, including platelet derivatives and hu-
man serum from autologous, allogeneic or cord blood
sources, are assessed in pre- and clinical studies to replace
FBS [8,9]. We have previously demonstrated that pooledtral Ltd. This is an open access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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thrombin-activated platelet releasate in plasma (tPRP) are
promising alternatives to FBS and support the main char-
acteristics of MSC [10-13]. Interestingly, HS, tPRP and
pHPL all promoted the proliferation of MSC from adipose
tissue (lipoaspirate, LA-MSC) to a comparable extent [13].
However, bone marrow-derived MSC (BM-MSC) prolifer-
ation was significantly enforced solely by pHPL [11]. The
different proliferative responses raised three questions:
i) which bioactive proteins differ in the lysate and the
releasate, ii) do these proteins exert different effects on
LA- and BM-MSC, and (iii) can we extrapolate these find-
ings to optimize chemically-defined MSC media?
Human serum and platelet granules contain various
growth factors capable of promoting cell proliferation and
tissue regeneration [8]. Identification and characterization
of these factors was markedly achieved by bioinformatic
approaches integrating proteomic data sets from plasma,
serum, the entire platelet proteome and specific subpro-
teomes with functional data [14-18]. These analyses have
provided a comprehensive list of platelet and plasma pro-
teins and as such contributed significantly to our current
biomolecular understanding of these components and
their function in the human body. They support a systems
biology view on platelet protein function, network mod-
ules and enable evaluation of upcoming data sets [19,20].
Aiming to answer our questions we analyzed pHPL
and tPRP with a differential proteomic approach and
related the data to an in-depth catalog of human platelet
proteins [20]. Upon integrating our own data with exist-
ing datasets on platelet factors differentially released
upon activation [18,20-23], resulting potential bioactive
proteins were functionally assessed on LA- and BM-MSC
in vitro proliferation.
In addition, to validate our system we assessed the
effects of selected reference cytokines. We chose cyto-
kines described to enhance the proliferation of MSC
in the presence of FBS asking whether these exert
similar or different effects when added to pHPL or
tPRP supplement.
Results and discussion
Bioactive factors promoting MSC expansion
Human platelet derivates support the expansion of MSC
from different tissues without changing the differenti-
ation capacity and immunoregulatory properties when
compared to FBS supplementation (Additional file 1:
Figure S1) [11,13,24,25]. Confirming previous results,
pHPL-supplemented medium significantly promoted BM-
MSC proliferation compared to tPRP- and FBS (Figure 1B,
p < 0.05) [11]. In contrast, pHPL and tPRP accelerated the
proliferation of LA-MSC in a similar way when compared
to FBS (p < 0.05) [13]. The specifically enhanced prolif-
erative response of BM-MSC towards pHPL was dose-dependent, with 2.5% pHPL comparable to 10% tPRP or
10% FBS. Interestingly, in tPRP dose dependency was not
obvious within the range of 10-5%. Evaluating different
batches, there were no significant differences in the prolif-
erative response (not shown). These data clearly indicate
that pHPL and tPRP contain different bioactive factors
which specifically affect BM-MSC proliferation.
Mass spectrometric identification of differential proteins
in pHPL and tPRP
To detect and identify bioactive factors in pHPL and
tPRP, a differential proteomic 2D-DIGE approach was
performed (Figure 1A). After labelling pHPL and tPRP
with CyDyes and subsequent 2D separation, 47 differen-
tially occurring proteins were quantified by Delta 2D im-
aging software (Figure 2A). Selected differential proteins
of pHPL and tPRP were picked from the preparative gel
(Additional file 2: Figure S2) and subjected to MALDI-
TOF analysis. In total, 19 plus one differential protein spe-
cies were identified (Table 1, Figure 2A, Additional file 2:
Figure S2). Six proteins appeared higher in tPRP whereas
14 proteins were more abundant in pHPL. One protein
out of 20, Annexin A5, was not satisfactory identified by
MS (5.6% below scoring) and initially not considered as
identified, but subsequent Western blot analysis con-
firmed differential expression (Table 1, Figure 2B).
Verification of selected differential proteins
First, the 2D-DIGE results were verified by SDS-PAGE
and Western blot analysis in ∅ Alb/IgG-samples. Fi-
brinogen, apoA1, CLIC and also of Annexin A5 were
differentially concentrated in ∅ Alb/IgG pHPL and tPRP
samples (Figure 2B). Second, all proteins were analyzed
in the eight different pHPL and tPRP batches (non-∅
Alb/IgG) used as 10% supplement. CLIC1 was not detect-
able in the 10% supplemented medium and thus not fur-
ther analysed. Fibrinogen and apoA1 were non-uniformly
concentrated (Figure 3D). To define the concentration
of fibrinogen and apoA1, one batch was compared to
a dilution series of known concentrations of fibrino-
gen and apoA1 in SDS-PAGE and Western blotting. By
comparing band intensities a concentration of approxi-
mately 500 μg/ml fibrinogen in 10% pHPL and ap-
proximately 80 μg/ml apoA1 in 10% tPRP-supplemented
medium was rated (not shown).
Influence of selected identified proteins on MSC
proliferation
Since none of the identified proteins was yet known as a
mitogen for MSC, those described to affect the prolifera-
tion of other cell types were further analyzed [26-28]. To
assess their bioactivity, BM- and LA-MSC were cultured
in 5% pHPL, tPRP and FBS, respectively, plus an increas-
ing concentration of the selected candidate proteins. To
Figure 1 Experimental strategy and effect of human supplements on MSC proliferation. (A) Experimental strategy and (B) proliferation of
MSC affected by the use of different supplements. Cell numbers were determined by the CellTiter-Glo assay on day 3 after seeding 3000 cells/well.
Absolute MSC cell counts are shown related to decreasing supplement concentrations of pHPL, tPRP or FBS. Three independent experiments with
three replicates were performed (#: p < 0.05; ##: p < 0.01).
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Figure 2 Proteomics and western blot verification. (A) Differential 2D-DIGE proteome map of pHPL and tPRP platelet derivatives containing
bioactive factors. Differential proteins spots (a total of 47) were detected by utilizing strips from pH 4 to 7 and quantitative Delta 2D imaging
software (t-test p≤ 0.05). Proteins identified by mass spectrometry are specifically shown (no. in rectangle). (B) Complementary Western blot
verification of differential proteins in albumin and IgG depleted pHPL and tPRP samples. Different protein concentrations were loaded: α-fibrinogen
(2.5 μg protein/lane), α-apoA1 (2.5 μg protein/lane), α-CLIC (5 μg protein/lane), α-annexin A5 (30 μg protein/lane).
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all these experiments. Of note, none of the single candi-
date proteins was able to affect proliferation in completely
supplement-free conditions (not shown).
Fibrinogen
125 μg/ml Fibrinogen significantly stimulated LA-MSC
proliferation in all three supplements compared to the
unstimulated control (Figure 3A). BM-MSC exhibited
strong donor variation ranging from stimulation to inhib-
ition especially in pHPL. Fibrinogen can form a matrix to
support cell adhesion, migration, but also proliferation
[26,29]. It has already been shown to dose-dependently
control BM-MSC proliferation, to reduce it at high con-
centrations depending on the FBS concentration [30,31].
By differential DIGE/MS, we found a differential pattern of
fibrinogen species, thus spliced, truncated and posttransla-
tional modified proteins [32,33]. Single batch Western
blotting analysis failed to confirm DIGE/MS differential fi-
brinogen expression. Probably the primary anti-fibrinogen
antibody may not be selective for all the individual isoform
epitopes identified by DIGE/MS proteomics. The higher
concentration of fibrinogen gamma chain species in pHPL
well fits to the thrombin-induced conversion of fibrinogen
to fibrin, consequently removed as clot in tPRP. By ap-
plying platelet-specific systems biology analysis several
interaction partners of fibrinogen gamma such as ICAM1(Intercellular Adhesion Molecule 1) or integrin beta 3
(CD61), known to be involved in rapid platelet aggrega-
tion, have been identified (Figure 3E).
Apolipoprotein A1
Only in FBS MSC proliferation became significantly
affected by ApoA1, which selectively promoted LA-MSC
but inhibited BM-MSC proliferation (Figure 3B). These
observations illustrate the differences in MSC tissue
source and supplements, respectively. ApoA1, a known
major component of high density lipoprotein (HDL), has
been reported to promote proliferation and to inhibit
apoptosis of endothelial and vascular smooth muscle
cells and to induce cardiac differentiation of embryonic
stem cells [27]. Several functional interaction partners
like Apo A1 binding protein and lipopolysaccharide
binding protein are depicted in Figure 3F after perform-
ing platelet-specific systems biology analysis [20].
ATP
Apart from the proteins identified by the proteomic ap-
proach, the ATP-based CellTiter-Glo assay indicated higher
ATP concentrations in tPRP supplement (6/8 batches;
176.5 ± 110.7 nM in tPRP and 52.3 ± 34.9 nM in pHPL).
Extracellular ATP (eATP) has been described to affect
various cellular features such as proliferation, apoptosis
and arrest of growth, especially in neural cells [34]. In
Table 1 MS analysis of 20 (19) differential protein spot species in pHPL and tPRPa) b)
Ratio
‘pHPL’/‘tPRP’











0.62 1 Apolipoprotein A-I sp|P02647|APOA1_HUMAN 80 29 33.7 292 30759 5.56
0.65 2 Apolipoprotein A-I sp|P02647|APOA1_HUMAN 64 23 26.4 205 30759 5.56
0.69 3 Retinol-binding protein 4 sp|P02753|RET4_HUMAN 67 11 15.3 114 23337 5.76
0.71 4 Angiotensinogen sp|P01019|ANGT_HUMAN 19 9 14.8 62 53406 5.87
0.71 5 CD5 antigen-like sp|O43866|CD5L_HUMAN 28 8 9 66 39603 5,28
0.74 6 Apolipoprotein A-I sp|P02647|APOA1_HUMAN 59 23 29.5 193 30759 5.56
1.55 7 Vitamin D-binding protein sp|P02774|VTDB_HUMAN 37 15 35.7 147 54526 5.40
1.84 8 Hemopexin sp|P02790|HEMO_HUMAN 25 9 10.1 68 52385 6.55
2.68 9 Fibrinogen gamma chain sp|P02679|FIBG_HUMAN 59 21 25.3 201 52106 5.37
2.77 10 Fibrinogen gamma chain sp|P02679|FIBG_HUMAN 56 21 23.1 226 52106 5.37
2.98 11 Tropomyosin alpha-4 chain sp|P67936|TPM4_HUMAN 33 10 17.2 83 28619 4.67
3.35 12 Fibrinogen gamma chain sp|P02679|FIBG_HUMAN 27 13 15.1 88 52106 5.37
4.30 13 Tubulin beta chain sp|P07437|TBB5_HUMAN 39 17 20.7 149 50095 4.78
4.59 14 Fibrinogen gamma chain sp|P02679|FIBG_HUMAN 56 21 24.1 235 52106 5.37
6.00 15 Fibrinogen gamma chain sp|P02679|FIBG_HUMAN 51 19 22.1 189 52106 5.37
6.69 16 Fibrinogen gamma chain sp|P02679|FIBG_HUMAN 27 11 16.7 73 52106 5.37
10.36 17 Chloride intracellular
channel protein 1
sp|O00299|CLIC1_HUMAN 43 9 18 88 27248 5.09
10.76 18 Actin, cytoplasmic 1 sp|P60709|ACTB_HUMAN 53 16 22.2 134 42052 5.29
11.01 19b) Annexin A5 sp|P08758|ANXA5_HUMAN 21 5 10.4 53b) 35971 4.94
12.27 20 Actin, cytoplasmic 1 sp|P60709|ACTB_HUMAN 52 18 27.3 163 42052 5.29
a)Mascot software analysis by using SwissProt data base. Ratio pHPL/tPRP: <1 higher abundant in tPRP, >1 higher abundant in pHPL. PMF criteria: human source,
one missed tryptic cleavage, methionine oxidation, score limit >56. b)Despite the fact that potential MS identification of Annexin A5 is below required scoring
(5.6% less), this non-significant MS hit was included into the list because the suggested high ratio and protein ID was confirmed by Western blotting.
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with decreased proliferation, reversible by P2 and P2Y1
antagonists [35]. Whereas this inhibitory effect of high
ATP concentrations of 106 nM was reproducible in all
three supplements for BM-MSC [35,36], LA-MSC in FBS
appeared refractory to growth inhibition (Figure 3C). The
distinct effects of eATP on different cell types have been
attributed to engagement of different purinergic receptors
[37,38].
Besides the current experimental limitations (depletion
of abundant proteins, no membrane proteins expected,
whole protein-based proteomics, selected pH range 4–7
of IEF), we are confident that the combination of differ-
ential proteomics, database comparison and functional
testing proves to be a suitable method to identify rele-
vant factors affecting MSC proliferation. Despite the few
factors tested, we were able to identify some with differ-
ential effects on MSC proliferation depending on the
supplement and MSC tissue source. Thus, the major
hurdle in developing a chemically-defined medium is the
combination and interaction of different factors which
can best be modeled by multifactorial design experi-
ments [39].Influence of selected reference cytokines on MSC
proliferation
Cytokines were not identified within the current 2D
DIGE approach probably due to their often low concen-
tration in plasma. Therefore, within a second set of
experiments selected cytokines, known to foster MSC
proliferation in FBS [40-42], were added to the different
supplements and MSC proliferation was measured. Here
we a) tested the effect of adding different concentrations
of cytokines, b) evaluated growth factor receptor expres-
sion and c) the concentration of cytokines in the cul-
ture medium/conditionened medium. We decided to
use 50 ng/ml HGF, 10 ng/ml IGF-1 and 25 ng/ml bFGF
[35,40,41]. Cytokines failed to induce a proliferative re-
sponse in MSC cultured with 5% platelet derivatives
(Figure 4A), whereas control cells in 5% FBS responded
adequately. bFGF inhibited BM-MSC proliferation in
the human supplements. Comparable findings have been
observed by Cheon et al. testing the effects of EGF, FGF
and ITS (insulin, transferring, selenium) on AT-MSC pro-
liferation in FBS or human serum. In both settings, the
combination of ITS and growth factors induced prolifera-
tion, whereas FGF on its own was highly effective in FBS
Figure 3 Influence of identified proteins and ATP on MSC proliferation. (A-C) MSC were seeded in 5% pHPL, tPRP and FBS, respectively,
and stimulated for 3 days with: (A) 125, 250 and 500 μg/ml fibrinogen, (B) 20, 40 and 80 μg/ml apoA1 and (C) 45, 90, 180, and 106 nM ATP.
Cell counts were measured using the CellTiter-Glo assay and then normalized to the unstimulated control to calculate relative cell count values.
Symbols indicate statistically significant diffences between: * stimulation; + supplements; # MSC sources; (one symbol p < 0.05; two symbols
p < 0.01). (D) Western blot verification of differentially expressed proteins, fibrinogen and apo-A1 in pHPL and tPRP (2.5 μg protein/lane, eight
different batches, respectively). Functional platelet interaction network analysis for fibinogen gamma (E) and apolipoprotein A1 (F) was performed
using PlateletWeb and subnet extraction according to Boyanova et al. [20] (white circles denote platelet proteins with no detected phosphoryl-
ation sites; black circles denote platelet proteins with phosphorylation sites detected in platelets; grey circles denote platelet proteins with phos-
phorylation sites detected in human cells).
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Figure 4 (See legend on next page.)
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Figure 4 Influence of selected cytokines on MSC proliferation; receptor expression profiles and concentration. (A) MSC were seeded in
5% pHPL, tPRP and FBS, respectively, and stimulated with for 3 days with 50 ng/ml HGF, 10 ng/ml IGF-1 or 25 ng/ml bFGF. Cell counts were
acquired with the CellTiter-Glo assay and then normalized to the unstimulated control to derive relative cell count values. (B)% positivity of IGF,
FGF and HGF receptor expression of BM- and LA-MSC (donors 1–3, respectively) in pHPL, tPRP and FBS assessed by flow cytometry. (C – E): IGF,
FGF and HGF concentrations were determined by ELISA in pHPL and tPRP supplemented medium (medium, 6 different batches); medium stored
for 24 h (control medium) and conditioned by MSC (CM) (each n = 3). Symbols indicate statistically significant diffences between: * stimulation;
+ supplements; # MSC sources; (one symbol p < 0.05; two symbols p < 0.01).
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platelet poor plasma, however, reached a proliferation rate
comparable to FBS [44], advising a fine tuning in multifac-
torial design studies.
Since cytokine effects depend on their concentration
as well as the receptor expression, flow cytometry ana-
lysis was performed to assess expression of growth factor
receptors. FGFRII and HGFR were expressed at a sig-
nificantly lower number of LA-MSC in FBS (similar, but
not significant in BM-MSC) (Figure 4B). Interestingly,
bFGF only induced proliferation in FBS, where both MSC
types had the lowest proportion of cells expressing FGFRII
(approx. 10%). The higher proportion of FGFRII ex-
pression in the human supplements possibly rendered
MSC unresponsive to additional bFGF. PDGFR-α expres-
sion appeared to be slightly higher in FBS, whereas
PDGFR-β and TGF-βRII were expressed similar to FGFRII
and HGFR (Additional file 3: Figure S3). With the excep-
tion of PDGFR-β in FBS, no differences between BM- and
LA-MSC were observed.
In previous studies, we addressed the cytokine content
in pHPL, tPRP and conditioned media of MSC but failed
to explain differential effects of pHPL and tPRP on MSC
proliferation [13]. We now further analyzed the levels of
selected candidates, including HGF, IGF-1, bFGF, PDGF-
AA, AB and BB and TGF-βII in fresh medium with 10%
supplement (medium), in medium incubated for 24 h
without cells (control medium) or in medium conditioned
by MSC (conditioned medium, CM). TGF-βII was not
detectable in any of the samples. IGF-1 concentrations
remained largely unaffected in all conditions (Figure 4C).
bFGF was detectable only in the pHPL setting, signifi-
cantly diminished by BM-MSC (Figure 4D). HGF was only
detectable in CM with apparent differences between
BM- and LA-MSC in pHPL, but not in tPRP (Figure 4E).
PDGF-AA levels were comparable in pHPL at all four
conditions, but in tPRP values dropped in control medium
to yield significant differences compared to pHPL. PDGF-
AB levels, although initially comparable between pHPL
and tPRP, became strongly reduced in tPRP control
medium. Similar data were obtained for PDGF-BB, with
differences in pHPL CM between BM- and LA-MSC
(Additional file 3: Figure S3).
Individual experimental conditions such as donor vari-
ability, but obviously also the MSC tissue origin, canlargely affect the outcome as indicated in this study.
Reported concentrations of cytokines in the supplements
vary enormously and so do the concentrations used to
stimulate MSC [45]. Numerous data indicate a strong
positive effect of bFGF on MSC proliferation and osteo-
genic differentiation, either alone or in combination with
TGF-β1 [40,46]. Platelet lysate-induced BM-MSC prolif-
eration can be inhibited by 75% by combining neutraliz-
ing antibodies against PDGF-AB/BB, TGF-β1 and bFGF.
Stimulation with these three factors alone, however, was
insufficient to promote proliferation [45]. This is in line
with the data presented herein.
Conclusion
Human supplements, such as platelet derivatives, are
emerging as alternatives to FBS in clinical-scale MSC
manufacturing. Observed differences in the proliferative
response of BM- and LA-MSC towards platelet lysate
versus platelet releasate prompted us to initiate a pro-
teomic screen of differentially expressed proteins. Al-
though the identified differential proteins have not been
previously shown to affect MSC expansion, bioactivity
testing confirmed differential effects of identified pro-
teins and selected cytokines on BM- and LA-MSC in the
context of supplement (FBS vs pHPL vs tPRP).
We are confident that combining already existing data
on MSC mitogens and platelet and plasma proteome
databases with the current data on identified proteins
and their differential bioactivity will provide a platform
to identify novel factors to optimize and standardize
BM- and LA-MSC culture conditions for safer clinical
application.
Methods
The work involving human material has been carried
out in accordance with The Code of Ethics of the World
Medical Association (Declaration of Helsinki) for experi-
ments involving humans. Use of human material has
been approved by the Medical Ethical Committee II in
Mannheim. Informed consent has been obtained prior
to cells/tissue collection.
Preparation of platelet derivates: pHPL and tPRP
Buffy coat-derived pooled platelet concentrates (pools of
four healthy blood donors, all fulfilling the criteria for
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from one donor [13]. To further minimize donor vari-
ability, each batch was prepared by pooling two platelet
concentrates. To assess variability between batches, eight
different pooled batches have been analyzed.
Each batch was then split into two parts. To yield the
whole platelet lysate pHPL, one part was processed by a
freezing and thawing step at −30°C and 37°C. The other
part was activated with 100U/ml thrombin from human
plasma (Merck) for 60 min under gentle agitation to
derive the releasate tPRP, containing only the released
platelet proteins in plasma. Here, in contrast to the
pHPL, a fibrin clot was formed and depleted by centrifu-
gation affecting the relative composition of platelet and
plasma factors compared to pHPL. Further processing
was standardized for both derivatives: samples were
centrifuged at 2000 g, 20 min at RT, supernatant was
aliquoted and cryopreserved at −30°C. Prior to use,
derivatives were gently thawed and centrifuged at 2000 g
for 10 min. To prevent clotting, DMEM medium (Lonza,
supplemented with 100 U/ml penicillin, 0.1 mg/ml
streptomycin and 4 mM L-glutamine (all from PAA) was
added with 5 IU/ml heparin (Ratiopharm). The respect-
ive supplement was added at the indicated concentration
and then the medium filtered through a 0.45 μm filter.
pHPL- and tPRP was always prepared fresh and used
within 24 hours.
Isolation and expansion of MSC
Adipose tissue was collected from three female donors
undergoing elective tumescence liposuction of the abdo-
men and hip/thigh region. BM aspirates were obtained
from three healthy donors in the department of Internal
Medicine V at the University Hospital of Heidelberg by
puncturing the iliac crest. LA-MSC and BM-MSC were
isolated by collagenase digestion or density gradient cen-
trifugation (Ficoll-Paque Plus =1.078 g/ml, GE Healthcare)
respectively as described previously [10,11,13,47]. Pri-
mary cells were seeded in 10% pHPL, tPRP and FBS
(PromoCell), respectively. At a confluence of 70-80%,
cells were passaged using trypsin-EDTA (PAA) and ei-
ther replated at a density of 200 cells per cm2 for all
passages or used for experiments. MSC were charac-
terized regarding the proliferation capacity, immune
phenotype, adipo- and osteogenic differentiation potential
(Additional file 1: Figure S1), according to previously de-




To deplete abundant proteins, pHPL and tPRP, each pooled
from two batches (a total of 16 donors and plasma from 4
donors), were pretreated with Albumin/IgG Depletion Kit(GE Healthcare; ∅ Alb/IgG) according to the manufac-
turer’s instruction (Figure 1A). Samples were mixed with
prefrozen acetone/methanol (v/v 8:1) for 3 h at −30°C and
subsequently centrifuged at 10000 g for 1 h at 4°C. After
washing with 500 μl ice-cold acetone and centrifugation
(10000 g, 10 min, 4°C), the pellet was air dried and resus-
pended in rehydration buffer (6 M urea, 2 M thiourea,
2% CHAPS (all Roth), 0.002% bromophenol blue (Sigma-
Aldrich).
Two-dimensional difference gel electrophoresis
To separate, quantify and identify differential protein
signatures and protein species in ∅ Alb/IgG pHPL and
in ∅ Alb/IgG tPRP, multiparametric 2D-DIGE (two-
dimensional difference gel electrophoresis) was per-
formed [32,33,48,49]. Thus, 50 μg protein of each sam-
ple was labelled with CyDye DIGE Fluors (Cy3, Cy5,
respectively, GE Healthcare) according to the Minimal
labeling protocol (GE Healthcare). For an internal stand-
ard, equal amounts of pHPL and tPRP were mixed and
50 μg from this mix labelled with Cy2. Labelled platelet
derivate samples and internal standard were pooled
equally to a final protein quantity of 150 μg. Rehydration
buffer with 32 mM DTT (Roth) and 0.5% IPG buffer
(pH 4–7, BioRad) was added to a final volume of 450 μl.
After 24 h rehydration, the 24 cm IPG-strips (pH 4–7,
BioRad) were subjected to isoelectric focussing on an
IPGphor (GE Healtcare) for a total of 58000 V/h. This
specific range of pH (pH 4–7) was chosen, since most of
the proteins seem to occur in this isoelectric window,
after testing IPG-strips with a range from pH 3–10 (data
not shown). Then each strip was equilibrated in 15 ml
equilibration buffer (6 M urea, 30% glycerol, 2% SDS,
50 mM Tris (pH 8.8), 0.002% bromophenol blue, all
Serva), first with 32 mM DTT for 20 min, second with
135 mM iodoacetamide (Roth). Equilibrated strips were
transferred onto a homogenous precast 12% bis-tris
polyacrylamide gel (1 mm, Serva) and sealed with agar-
ose (1% agarose, 0.002% bromophenol blue, Roth). SDS-
PAGE was performed with constant 17 W per gel and a
running time until the blue front ran out of the gels
(Ettan DALT II system; GE Healthcare). Three replicates
were run.
Advanced image warping and quantitative protein analysis
Visualization of labelled protein spots was performed
with a fluorescence scanner (FujiFilm FLA-5100). There-
fore, gels were scanned with three different fluorescence
filters (Cy2: Ex. 488 nm, Em. 520 nm, Filter Y520/LBB;
Cy3: Ex. 532 nm, Em. 580 nm, Filter O580/DGR1; Cy5:
Ex. 633 nm, Em. 670 nm, Filter R665/LPR). Sensitivity
was set on 400 V with 50 μm pixel/resolution. Spot
detection, warping, and statistical analysis of stained
or labeled samples were performed using Delta2D 3.4
Kinzebach et al. BMC Cell Biology 2013, 14:48 Page 10 of 13
http://www.biomedcentral.com/1471-2121/14/48software (Decodon) as described previously [50]. For
significant differential protein spot detection, sensitivity,
background settings, and spot size were chosen according
to the manufacturer’s instruction. Images were matched
using stringent warping strategy. Regulation factor was set
to 1 +/− 0.5 (red spots >1.5; green spots <0.8; and yellow
spots <1.5, >0.8).
Mass spectrometry and protein identification
Preparative gels were run (250 μg protein/gel), fixed with
methanol/acetic acid/H2O (40/10/50%), stained with
Sybro Ruby (GE Healthcare) and scanned at 618 nm. In
addition, a sensitive coomassie G250 blue staining was
performed. Matched protein spots of interest were picked
manually and subjected to an in-gel tryptic digestion as
described previously [51]. Briefly, after washing (100 μl
H2O, 8 min, 37°C, 600 rpm), picked spots were incubated
in 200 μl 40 mM NH4HCO3/CAN (acetonitrile) (v/v 1:1)
for 15 min (25°C, 600 rpm). After incubation with ACN
(1 min, 600 rpm, RT), protein spots were air dried for
5 min. For peptide mass fingerprint mapping 10 μl trypsin
(3.5 μg/μl, Promega) was added for 30 min at 4°C. Exces-
sive trypsin was removed and 10 μl 40 mM NH4HCO3
added and incubated over night at 37°C. Samples were
stored at −30°C.
Before MALDI analyses of digested human platelet
proteins, peptides were concentrated and manually
desalted using ZipTip® pipette C18 columns (Millipore).
Peptides were eluted with 1 mL α-cyano-4-hydroxycin-
namic acid diluted 1:7 in 1:1 ACN/0.1% trifluoracetic
acid solution and spotted on a MALDI 800–384 anchor
chip target plate and analyzed automatically on a Bruker
Ultraflex II using flex control, flex analysis, and Bruker
BioTools software (batchmode). For external calibration,
peptide calibration standard II was used (Sigma; m/z ra-
tio from 700 to 3500) [50]. Database searches were per-
formed using MS ion search against all entries for Homo
sapiens in the Swiss-Prot database, applying the follow-
ing: tryptic digest, up to one missed cleavage; fixed mod-
ifications, carbamidomethyl (C); variable modification,
and oxidation at methionine (M). Mass tolerance was set
to 7100 ppm. Identification was taken as unambiguous if
the Mowse score was at least 56 (with p-value < 0.05). In
addition, PMF identification was verified comparing mo-
lecular weight and pI of the identified protein with gel
position of the according protein spot.
Data verification by Western Blot analysis
Proteins were lysed in RIPA buffer (Santa Cruz Biotech).
Protein concentration was measured by Bradford protein
assay (Bio-Rad) and adjusted to equal concentrations.
Protein lysates were mixed with loading buffer (Fermentas),
separated on 12% Bis-Tris gels and then transferred onto a
PVDF membrane (GE Healthcare). Primary antibodies usedwere: α-Fibrinogen-Biotin pAB (IMS06-038-312, Agrisera),
α-Apolipoprotein A1 pAB (178422, Calbiochem), α-CLIC-1
(chloride intracellular channel 1; 356.1, Santa Cruz Bio-
tech). HRP-conjugated secondary reagents used were α-
Mouse IgG, α-Rabbit IgG (both Dako) and Streptavidin
(Calbiochem). All antibodies were dissolved in TBS, 5%
skimmed milk powder, 0.05% Tween-20 (all Roth). Band
detection was performed using enhanced chemilumines-
cence reagent (Amersham™ ECL™ Select Western Blotting
Detection Reagent, GE Healthcare). Loading concentra-
tions were assessed by Ponceau S staining and reference
controls (Serva dual color protein standard III, Serva).
Proliferation and stimulation assay
To determine the proliferation rate of MSC, CellTiter-
Glo™ assay (Promega) quantifying ATP was performed.
MSC in passage 2 with 70% confluence were trypsinized
and seeded at a density of 3000 cells for 3 days into a black
96 well plate (Iso plate, PerkinElmer). Culture medium
was either supplemented with each 10%, 7.5%, 5%, 2.5%
pHPL, tPRP or FBS, respectively. Stimulation experi-
ments utilized 5% of the supplements and the following
substances at the indicated concentrations: fibrinogen,
apolipoprotein A1 (apoA1), adenosine triphosphate (ATP)
(Roche) and in a second set of experiments hepatocyte
growth factor (HGF), insulin-like growth factor 1 (IGF-1)
(all Calbiochem), and basic fibroblast growth factor (bFGF)
(Miltenyi Biotec).
Enzyme-linked immunosorbent assay (ELISA)
In order to detect cytokines, described to induce MSC
proliferation, platelet derivates (pHPL, tPRP n = 6; FBS
n = 2) as well as medium of MSC (BM-, LA-MSC in
FBS, pHPL, tPRP, each n = 3), conditioned for 24 h, were
tested for PDGF-AA, AB, BB; IGF-1; HGF, bFGF
(all Quantikine ELISA kit, R&D Systems) by ELISA
according to the manufacturer’s instructions.
Flow cytometry
To assess the expression of cytokine receptors, flow cyto-
metric analyses were performed. MSC were double-stained
in 100 μl cell wash (BD) with the following phycoerythrin-
(PE) and allophycocyanin- (APC) labelled antibodies:
PDGFR-α-PE (16A1), PDGFR-β-APC (18A2, both bio-
legend), TGF-βRII-PE (FAB2411P; R&D systems), IGFR-1-
APC (1H7; eBioscience), HGFR-APC (FAB35821), FGFR-PE
(FAB684P; both R&D systems). 7-Aminoactinomycin D
was used for dead cell exclusion (Beckman Coulter). Stained
cells were analyzed with the FACS Canto II from BD.
Statistical analysis
Statistical tests were performed using SigmaPlot 11.0
(Systat Software Inc). Data was tested for normality and
equal variance before analysis. Statistical differences
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variance (ANOVA, Holm-Sidak method; or ANOVA on
ranks if equal variance testing failed, Tukey method).
Comparing two samples paired or unpaired t-tests, re-
spectively, were used. The symbols indicate: (*) significant
difference before and after stimulation; (+) significant
difference between supplements; (#) significant difference
between MSC sources.Additional files
Additional file 1: Figure S1. Phenotype, differentiation potential and
immunosuppressive activity LA- and BM-MSC were cultured in 10% FBS,
pHPL and tPRP, respectively. (A) Photos were taken at identical time
points post-seeding to observe cell morphology and confluence. Repre-
sentative pictures of one LA-MSC and one BM-MSC batch are depicted
(all 100× magnification). (B) Adipogenic and osteogenic differentiation.
Cells were induced with differentiation media (adipogenic induction and
maintance medium for 3 and 4 days, respectively and osteogenic induc-
tion medium, all Lonza) for 3 weeks and then stained with oil red o and
van Kossa as descried previously [11,13]. Representative results of one
LA-MSC batch are depicted (100× magnification). (C) Immunosuppressive
activity was assessed by coculturing LA-MSC (ratio 1:10) with allogeneic
peripheral blood leukocytes labeled with carboxyfluorescein diacetate
succinimidyl ester (5 μM, Vybrant CFDA-SE cell tracker kit, Invitrogen).
Leukocyte proliferation was stimulated with phytohemagglutinin
(2.5 μg/ml PHA-L, Roche Applied Science) and assessed by progressive
halving of CFDA-SE fluorescence (red line – control with PHA; green –
control without PHA). One representative experiment is depicted reveal-
ing similar dye retention and thus immunosuppressive activity of MSC in
FBS, pHPL and tPRP (grey line – coculture MSC with PHA). Similar data
were obtained applying BM-MSC.
Additional file 2: Figure S2. Representative 2D-gel of pHPL and PRP
samples. Spots marked in green occurred at higher concentrations in
tPRP as compared to pHPL, whereas spots marked in red were more
abundant in pHPL (pH 4–7; 24 cm strip; Sybro Ruby staining).
Additional file 3: Figure S3. Cytokines and receptor expression. (A)
Flow cytometry to determine PDGFs and TGF-βII receptor expression
(% positivity) of BM- and LA-MSC in pHPL, tPRP and FBS. (B – D) Deter-
mination of PDGF-AA, AB, BB concentrations in six different pHPL and
tPRP batches (10% supplemented medium); medium stored for 24 h
(control medium) and conditioned medium by MSC (CM) via ELISA.
Symbols indicate statistically significant diffences between: * stimulation;
+ supplements; # MSC sources; (one symbol p < 0.05; two symbols
p < 0.01; n = 3 for each condition).Abbreviations
ACN: Acetonitrile; APC: Allophycocyanin; apoA1: Apolipoprotein A1;
ATP: Adenosine triphosphate, bFGF, Basic fibroblast growth factor; BM-
MSC: Bone marrow-derived mesenchymal stromal cells; CLIC-1: Chloride
intracellular channel 1; CM: Conditioned medium; Cy: CyDye;
FGFRII: Fibroblast growth factor receptor II; GMP: Good manufacturing
practice; HGF: Hepatocyte growth factor; HGFR: Hepatocyte growth factor
receptor, c-met; IGF-1: Insulin-like growth factor 1; IGFR-1: IGF-1 receptor 1;
LA-MSC: Lipoaspirate-derived MSC, adipose tissue-derived MSC;
MSC: Mesenchymal stromal cells; PDGF-AA, AB, BB: Platelet-derived growth
factor; PDGFR-αβ: PDGF receptor; PE: Phycoerythrin; pHPL: Pooled human
platelet lysate; TGF-βΙΙ: Transforming growth factor beta II; TGF-βRII: TGF-β
receptor II; tPRP: Thrombin-activated platelet releasate in plasma; ØAlb/
IgG: Albumin and IgG depleted.Competing interests
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